EGFR vIII, Human, 重组蛋白 (hFc) TMPJ-00647

Product Introduction
Bioactivity


英文名: EGFR vIII Protein, Human, Recombinant (hFc)

描述: The EGFR subfamily of receptor tyrosine kinases is composed of EGFR, ErbB2, ErbB3 and ErbB4. The EGFR shares 43% - 44% aa sequence identity with the ECD of human EGFR subfamily. All these family members are type I transmembrane glycoproteins with an extracellular ligand binding domain. The extracellular ligand binding domain is containing two cysteine-rich domains separated by a spacer region and a cytoplasmic domain containing a membrane-proximal tyrosine kinase domain. Ligand binding could induce EGFR homodimerization and heterodimerization with ErbB2, resulting in cell signaling, heterodimerization tyrosine phosphorylation and kinase activation. It can bind EGF, amphiregulin, TGF-alpha, betacellulin, epiregulin, HB-EGF, epigen, and so on. Its signaling regulates multiple biological functions including cell proliferation, differentiation, motility, and apoptosis. EGFR can also be recruited to form heterodimers with the ligand-activated ErbB3 or ErbB4. EGFR is overexpressed in different tumors. Several anti-cancer drugs use EGFR as target.

存储条件: Lyophilized powder: -20~-80°C for 1 year | Solution: -80°C for 6~12 month

EGFR vIII, Human, 重组蛋白 (hFc) TMPJ-00647信息由TargetMol中国为您提供，如您想了解更多关于EGFR vIII, Human, 重组蛋白 (hFc) TMPJ-00647报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途